UY27198A1 - Nuevos compuestos antiinflamatorios de bencimidazol - Google Patents

Nuevos compuestos antiinflamatorios de bencimidazol

Info

Publication number
UY27198A1
UY27198A1 UY27198A UY27198A UY27198A1 UY 27198 A1 UY27198 A1 UY 27198A1 UY 27198 A UY27198 A UY 27198A UY 27198 A UY27198 A UY 27198A UY 27198 A1 UY27198 A1 UY 27198A1
Authority
UY
Uruguay
Prior art keywords
bencimidazol
new
inflammatory compounds
alkyl
nitrogen
Prior art date
Application number
UY27198A
Other languages
English (en)
Inventor
Mark Anthony Dombroski
Michael Anthony Letavic
Kim Francis Mcclure
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27198A1 publication Critical patent/UY27198A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Triazolopiridinas de fórmula I, en que Het es heterociclo de 5 miembros opcionalmente sustituido conteniendo uno o dos heteroátomos seleccionados entre nitrógeno, azufre y oxígeno, siendo al menos uno de ellos nitrógeno; R2 selecionado del grupo compuesto por hidrógeno, alquilo (C1-C6) u otros sustituyentes adecuados; R3 selecionado del grupo compuesto por hidrógeno, alquilo (C1-C6) u otros sustituyentes adecuados. S número entero de 0,5. Composiciones conteniéndolos y su uso en medicina, como potentes inhibidores de MAP quinasas, preferiblemente de quinasa P38, y útiles para tratar inflamación, osteoporosis, artritis reumatoide, cáncer, repercusión o isquemia en apoplejía o en ataque cardíaco, enfermedades autoinmunes y otras.
UY27198A 2001-03-09 2002-03-06 Nuevos compuestos antiinflamatorios de bencimidazol UY27198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27479101P 2001-03-09 2001-03-09

Publications (1)

Publication Number Publication Date
UY27198A1 true UY27198A1 (es) 2002-11-29

Family

ID=23049627

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27198A UY27198A1 (es) 2001-03-09 2002-03-06 Nuevos compuestos antiinflamatorios de bencimidazol

Country Status (17)

Country Link
US (1) US7056918B2 (es)
EP (1) EP1370557B1 (es)
JP (1) JP2004526727A (es)
AP (1) AP2002002460A0 (es)
AT (1) ATE309997T1 (es)
BR (1) BR0207957A (es)
CA (1) CA2440211A1 (es)
DE (1) DE60207390T2 (es)
DO (1) DOP2002000349A (es)
ES (1) ES2251582T3 (es)
GT (1) GT200200043A (es)
MX (1) MXPA03008142A (es)
PA (1) PA8540901A1 (es)
PE (1) PE20030200A1 (es)
TN (1) TNSN02021A1 (es)
UY (1) UY27198A1 (es)
WO (1) WO2002072576A1 (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
EP1554272B1 (en) * 2002-08-09 2006-10-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
CN101870691A (zh) 2002-08-19 2010-10-27 劳洛斯治疗公司 2,4,5-三取代的咪唑及其作为抗菌剂的用途
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
CA2498047C (en) 2002-09-18 2009-05-19 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
EA200500377A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
CA2515190A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
DE10315569A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
JP2007500245A (ja) * 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
GB0313914D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
US7157471B2 (en) * 2003-08-25 2007-01-02 Boehringer Ingelheim International Gmbh Haloalkyl- and piperidine-substituted benzimidazole-derivatives
WO2005047266A1 (en) * 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
MXPA06007023A (es) * 2003-12-18 2006-08-31 Pfizer Prod Inc Metodos para tratar la inflamacion aguda en animales con inhibidores de p38 map cinasa.
US7863310B2 (en) 2004-02-03 2011-01-04 Eli Lilly And Company Kinase inhibitors
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7713998B2 (en) 2004-11-10 2010-05-11 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and pharmaceutical use thereof
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US8148392B2 (en) 2005-05-25 2012-04-03 Lorus Therapeutics Inc. 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer
WO2007015866A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
PE20070182A1 (es) 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
EP1934185A1 (en) 2005-08-12 2008-06-25 Synta Pharmaceuticals Corporation Pyrazole compounds that modulate hsp90 activity
EP1829867A1 (en) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
CA2653217A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
KR100832747B1 (ko) * 2006-10-27 2008-05-27 한국화학연구원 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
CA2747784C (en) * 2008-12-24 2018-07-31 Bial - Portela & Ca, S.A. Imidazole compounds for use as enzyme inhibitors
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
EP2603079B1 (en) * 2010-08-12 2018-09-19 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
RU2454235C2 (ru) * 2010-10-11 2012-06-27 Елена Сергеевна Кипарисова Способ лечения пациентов с острой цереброваскулярной патологией на фоне посттравматического стрессового расстройства, выполняемый комбинированной психомедикаментозной терапией
TWI410425B (zh) * 2010-12-03 2013-10-01 Lilly Co Eli 唑并［５，４－ｂ］吡啶－５－基化合物
KR101316101B1 (ko) * 2011-05-26 2013-10-11 연세대학교 산학협력단 Ｐｔｋ 6의 활성 억제용 조성물 및 이를 이용한 암 예방 및 치료용 조성물
UA114490C2 (uk) 2011-10-06 2017-06-26 Байєр Інтеллектуал Проперті Гмбх Гетероциклілпіри(mі)динілпіразоли як фунгіциди
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
AU2012332421A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors
JP2014533299A (ja) 2011-11-14 2014-12-11 シンタ ファーマシューティカルズ コーポレーション Ｂｒａｆ阻害剤とｈｓｐ９０阻害剤の組合せ療法
EP2858983B1 (en) * 2012-06-11 2018-04-18 UCB Biopharma SPRL Tnf-alpha modulating benzimidazoles
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
CN105308050A (zh) 2013-03-20 2016-02-03 艾普托斯生物科学公司 2-取代咪唑并[4,5-d]菲咯啉衍生物和其在治疗癌症中的用途
AU2014256633B2 (en) 2013-04-25 2017-02-02 Beigene Switzerland Gmbh Fused heterocyclic compounds as protein kinase inhibitors
CA2915622C (en) * 2013-06-21 2020-08-18 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
SG10201710705UA (en) 2013-06-21 2018-02-27 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
PL3702373T3 (pl) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
US20150104392A1 (en) 2013-10-04 2015-04-16 Aptose Biosciences Inc. Compositions, biomarkers and their use in the treatment of cancer
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
KR20170122799A (ko) 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-β 억제제
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
CN116478165A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
US10532986B2 (en) * 2016-08-22 2020-01-14 Medshine Discovery Inc. Cyclic compound acting as PDE4 inhibitor
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF
CN110799543A (zh) 2017-06-26 2020-02-14 百济神州有限公司 肝细胞癌的免疫治疗
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
DK3691620T3 (da) 2017-10-05 2022-10-03 Fulcrum Therapeutics Inc P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd
WO2019089511A1 (en) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
WO2019089734A1 (en) * 2017-10-31 2019-05-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for the treatment of influenza
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
CN109134431B (zh) * 2018-10-10 2021-06-04 成都理工大学 作为囊性纤维化跨膜传导调节因子抑制剂的氨基咪唑偶联吡啶酮衍生物
CN113557235A (zh) 2019-03-06 2021-10-26 C4医药公司 用于药物治疗的杂环化合物
EP3995490A4 (en) * 2019-07-04 2023-08-09 Medshine Discovery Inc. CRYSTAL FORM OF A BENZIMIDAZOLE-2-ONE COMPOUND, ITS SOLVATE, CRYSTAL FORM OR SOLVATE THEREOF AND PROCESS FOR THEIR PRODUCTION
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 ***氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
CA3185689A1 (en) * 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU667560A1 (ru) * 1977-08-08 1979-06-15 Тюменский государственный университет Способ получени полиметилметакрилата
US5716972A (en) 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
PT724588E (pt) 1993-09-17 2000-05-31 Smithkline Beecham Corp Proteina de ligacao a farmacos
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
KR19990077164A (ko) 1996-01-11 1999-10-25 스티븐 베네티아너 신규 치환된 이미다졸 화합물
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
JP2002516325A (ja) 1998-05-26 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規な置換イミダゾール化合物
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
ES2221426T3 (es) * 1998-08-20 2004-12-16 Smithkline Beecham Corporation Nuevos compuestos de triazol sustituidos.
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
CA2355075C (en) 1998-12-16 2009-12-08 Aventis Pharma Limited Heteroaryl-cyclic acetals
AU2408300A (en) 1999-01-08 2000-07-24 Smithkline Beecham Corporation Novel compounds
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
CO5170501A1 (es) * 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

Also Published As

Publication number Publication date
US7056918B2 (en) 2006-06-06
JP2004526727A (ja) 2004-09-02
ATE309997T1 (de) 2005-12-15
CA2440211A1 (en) 2002-09-19
ES2251582T3 (es) 2006-05-01
BR0207957A (pt) 2004-02-25
PE20030200A1 (es) 2003-03-12
EP1370557B1 (en) 2005-11-16
PA8540901A1 (es) 2002-10-28
TNSN02021A1 (fr) 2005-12-23
US20030092749A1 (en) 2003-05-15
EP1370557A1 (en) 2003-12-17
GT200200043A (es) 2003-02-11
DE60207390T2 (de) 2006-07-20
DOP2002000349A (es) 2002-10-15
WO2002072576A1 (en) 2002-09-19
AP2002002460A0 (en) 2002-06-30
MXPA03008142A (es) 2003-12-12
DE60207390D1 (de) 2005-12-22

Similar Documents

Publication Publication Date Title
UY27198A1 (es) Nuevos compuestos antiinflamatorios de bencimidazol
DOP2002000353A (es) Nuevos compuestos antiinflamatorios de triazolopiridinas
CA2379903A1 (en) Novel benzotriazoles anti-inflammatory compounds
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
GT200000002A (es) Ureas difenilicias x - carboxyaril sustituidas como inhibidores raf kinase.
AP2000001964A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
CO5261551A1 (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
AR035777A1 (es) Derivados de pirazol sustituidos, procesos para su preparacion, composiciones farmaceuticas que los contienen, y su uso en medicina
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
NO20023933D0 (no) Nye forbindelser
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
MA23433A1 (fr) Nouvelles compositions leurs procedes de preparation et leur emploi
YU50402A (sh) Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze
ATE397609T1 (de) Corticotropinfreisetzungsfaktor antagonisten
CO5251476A1 (es) Procedimiento para la preparacion de compuestos de pirazolo [4,3-d] pirimidin-7-onas-3-piridilsulfonilo e intermedios de los mismos
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
AR032341A1 (es) N-(2-metansulfonil-etil)-n-hidroxiformamidas, su uso en la produccion de medicamentos, composiciones farmaceuticas que las contienen, procedimiento para preparar dichos compuestos e intermediarios para su preparacion
AR044176A1 (es) Derivados de 3 -carbonilaminotiofeno y sus usos como funguicidas
AR035022A1 (es) Nitro-sulfobenzamidas, proceso para su fabricacion, y uso de estos compuestos para preparar sulfonilureas
UA90461C2 (en) Pyrazole derivatives as protein kinase modulators
SE9902147D0 (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma
DOP2003000693A (es) Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas
AR051782A1 (es) Compuesto heterociclico fusionado

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141112